1. Home
  2. ONC vs TW Comparison

ONC vs TW Comparison

Compare ONC & TW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • TW
  • Stock Information
  • Founded
  • ONC 2010
  • TW 1996
  • Country
  • ONC Switzerland
  • TW United States
  • Employees
  • ONC N/A
  • TW N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • TW Investment Bankers/Brokers/Service
  • Sector
  • ONC Health Care
  • TW Finance
  • Exchange
  • ONC Nasdaq
  • TW Nasdaq
  • Market Cap
  • ONC 26.9B
  • TW 28.0B
  • IPO Year
  • ONC N/A
  • TW 2019
  • Fundamental
  • Price
  • ONC $250.30
  • TW $135.79
  • Analyst Decision
  • ONC Strong Buy
  • TW Strong Buy
  • Analyst Count
  • ONC 9
  • TW 10
  • Target Price
  • ONC $325.56
  • TW $149.60
  • AVG Volume (30 Days)
  • ONC 345.1K
  • TW 1.3M
  • Earning Date
  • ONC 08-06-2025
  • TW 07-30-2025
  • Dividend Yield
  • ONC N/A
  • TW 0.35%
  • EPS Growth
  • ONC N/A
  • TW 29.22
  • EPS
  • ONC N/A
  • TW 2.43
  • Revenue
  • ONC $4,175,868,000.00
  • TW $1,823,739,000.00
  • Revenue This Year
  • ONC $869.15
  • TW $23.19
  • Revenue Next Year
  • ONC $19.07
  • TW $11.08
  • P/E Ratio
  • ONC N/A
  • TW $56.03
  • Revenue Growth
  • ONC 51.16
  • TW 28.94
  • 52 Week Low
  • ONC $146.21
  • TW $103.77
  • 52 Week High
  • ONC $287.88
  • TW $152.65
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • TW 43.07
  • Support Level
  • ONC N/A
  • TW $133.71
  • Resistance Level
  • ONC N/A
  • TW $137.34
  • Average True Range (ATR)
  • ONC 0.00
  • TW 3.87
  • MACD
  • ONC 0.00
  • TW -0.65
  • Stochastic Oscillator
  • ONC 0.00
  • TW 18.19

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About TW Tradeweb Markets Inc.

Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in U.S. and European government debt, mortgage-backed securities, interest-rate swaps, and U.S. and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.

Share on Social Networks: